Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkey
OBJECTIVE: Medikinet retard® is a nonosmotic, extended-release formulation of Methylphenidate (MPH) and has been used in Turkey for the last 4–5 years. The aim of our study is to compare the efficacy on functionality of Medikinet retard® and Concerta® and their adverse events. METHODS: Participants...
Main Authors: | Merve Cikili Uytun, Fatih Hilmi Çetin, Zehra Babadağı |
---|---|
Format: | Article |
Language: | English |
Published: |
AVES
2019-10-01
|
Series: | Psychiatry and Clinical Psychopharmacology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/24750573.2019.1609153 |
Similar Items
-
Increase in brain connectivity with methylphenidate treatment in boys diagnosed with attention deficit hyperactivity disorder: A coherence-based qeeg analysis
by: F.H. Çetin, et al.
Published: (2021-04-01) -
Decrease in brain complexity with methylphenidate treatment in boys diagnosed with attention deficit hyperactivity disorder: An entropy-based qeeg analysis
by: F.H. Çetin, et al.
Published: (2021-04-01) -
Associations between CES1 variants and dosing and adverse effects in children taking methylphenidate
by: Jacob T. Brown, et al.
Published: (2023-01-01) -
Editorial: Attention and Methylphenidate
by: Avi Avital, et al.
Published: (2020-04-01) -
A randomised controlled trial of combined EEG feedback and methylphenidate therapy for the treatment of ADHD
by: Li Li, et al.
Published: (2013-08-01)